• Basilea posted H1 2026 revenue up 14.4% to CHF 119 million; operating profit climbed 31.7% to CHF 31.6 million.
• Profit more than doubled to CHF 27.9 million; diluted EPS rose to CHF 2.13.
• R&D expense increased to CHF 54 million, mainly tied to two ongoing Phase 3 fosmanogepix studies.
• Liquidity rose 32.6% to CHF 176 million, while nominal financial debt fell to CHF 71 million after CHF 5 million convertible bond buybacks.
• Raised FY 2026 guidance: revenue seen up about 15% and operating profit up about 40%; fosmanogepix Phase 3 remains on track for 2028 filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180115OMX_____CNEWS_DE_GNW1001258048_de) on August 18, 2026, and is solely responsible for the information contained therein.